ROUND 05 // THE RECORD
BPC-157 TB-500: every question, answered from the record
Twenty-two direct answers on identity, mechanism, angiogenesis, dosing, safety, and legal status — each one tied to the studies or the FDA record.
Identity and difference
BPC-157 TB-500 questions cluster around one thing: this is two peptides, not one. The answers below start there.
What is BPC-157 and TB-500?
Two distinct synthetic peptides combined as a research blend. BPC-157 is a 15-amino-acid cytoprotective and angiogenic peptide (GEPPPGKPADDAGLV, ~1,419 Da). TB-500 is an N-acetylated 7-mer (Ac-LKKTETQ, ~889 Da) from the actin-binding region of Thymosin Beta-4. Different sequences, different mechanisms, paired as a stack.
What is the Wolverine peptide blend?
A research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed as a tissue-repair "stack." It is not a single chemical entity or an approved product. The term's search volume is heavily conflated with the comic-book character.
What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-amino-acid gastric-juice-derived cytoprotective and angiogenic peptide acting through VEGFR2-Akt-eNOS [2]. TB-500 is a 7-amino-acid actin-binding fragment of Thymosin Beta-4 acting on cytoskeletal migration through 1:1 G-actin sequestration [3]. Different sequences, different mechanisms.
Mechanism
How does TB-500 work (actin / Thymosin Beta-4)?
TB-500's LKKTETQ motif binds monomeric G-actin 1:1, sequestering it and regulating the cytoskeletal dynamics that drive cell migration and re-epithelialization. Structural work on Thymosin Beta-4 established this 1:1 capping mechanism at 2 angstroms [3].
How does BPC-157 work compared to TB-500?
BPC-157 acts as a local cytoprotective and pro-angiogenic signal (VEGFR2-Akt-eNOS, nitric-oxide modulation) [2], while TB-500 acts intracellularly on actin dynamics [3]. The two work through largely non-overlapping pathways.
Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)?
Both are reported to promote angiogenesis by distinct routes in animal and cell models: BPC-157 via VEGFR2-Akt-eNOS up-regulation [2], and TB-500/Thymosin Beta-4 via endothelial migration [6]. This is preclinical, not a human combination finding.
Why are BPC-157 and TB-500 combined (the Wolverine stack)?
The rationale pairs BPC-157's cytoprotective and angiogenic signal with TB-500's actin-driven cell-migration signal as complementary mechanisms. This "synergy" is a theoretical extrapolation from each peptide's separate mechanism, not a controlled-study finding [8].
Evidence and efficacy
Is there any study showing BPC-157 and TB-500 work better together (synergy)?
No. No peer-reviewed study defines a synergy ratio, dose, or endpoint for the two given together. A 2025 systematic review of BPC-157 makes no mention of TB-500 or combination use [8].
Are there human clinical trials on the BPC-157 + TB-500 combination?
There are no controlled human trials of the combination. Human data exist only for the individual constituents and are thin: three small BPC-157 pilots, and the human "TB-500" data are actually for full-length Thymosin Beta-4 [7].
What is the BPC-157 and TB-500 blend used for in research?
In animal models the constituents have been studied for tendon, ligament, muscle, and wound repair and for angiogenesis [1][4]. The blend itself has no controlled human efficacy data.
Does the BPC-157 TB-500 blend help tendon and ligament injuries?
In rodent models BPC-157 accelerated transected-Achilles-tendon and ligament healing [1], and Thymosin Beta-4 improved ligament and wound healing [4]. These are animal findings, not human or combination evidence.
Does BPC-157 and TB-500 help muscle tears and recovery?
Preclinical and review evidence describes musculoskeletal-repair effects for BPC-157, but recent reviews rate the evidence at the lowest tiers (level IV-V) with no clinical safety data [8]. Nothing addresses the blend in humans.
Dosing, handling, and pharmacokinetics
What is the half-life of BPC-157 and TB-500?
BPC-157's elimination half-life was reported as under 30 minutes in animal pharmacokinetic studies. No validated half-life is established for the TB-500 fragment, and none for the blend.
How do you reconstitute a BPC-157 / TB-500 blend (10mg)?
Both are supplied as lyophilized powders reconstituted in bacteriostatic or sterile water and refrigerated for research handling [7]. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed.
How often should you inject BPC-157 and TB-500?
There is no validated dosing schedule for the blend. Community "loading then maintenance" protocols have no controlled-trial basis [8] and should not be presented as validated dosing.
Safety and legal status
What are the side effects of BPC-157 and TB-500?
Long-term human safety is unknown for both constituents. The main flagged concern is a theoretical tumor and angiogenesis signal for Thymosin Beta-4 [4], and combining two unapproved peptides compounds the uncertainty [8].
Does TB-500 cause cancer or promote tumor growth?
Thymosin Beta-4 is implicated in tumor metastasis and angiogenesis, so the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression [4]. This is a flagged safety consideration, not a demonstrated human effect of the blend.
Is TB-500 bad for your heart?
Full-length Thymosin Beta-4 has been studied in cardiac-repair models and credited with regenerative activity [4], but no controlled data exist for the TB-500 fragment or the blend, so cardiovascular effects in humans are unestablished.
Are BPC-157 and TB-500 FDA approved or banned by WADA?
Neither is FDA-approved for human use; the FDA placed both in 503A Category 2 of bulk substances flagged for significant safety risks pending review [11], and both constituents are prohibited by WADA.
Is Wolverine legal?
The blend pairs two substances neither FDA-approved for human use, both in FDA 503A Category 2 [11], both WADA-prohibited; routine compounding access to the ingredients is currently restricted [12]. The status is under active FDA review with a July 2026 PCAC meeting scheduled as a discussion, not a decision [13].
Can you get BPC-157 from a compounding pharmacy?
Routine 503A compounding-pharmacy access to BPC-157 is currently restricted: it sits in Category 2 (flagged for significant safety risks) effective September 29, 2023, which is outside the enforcement-discretion policy for Category 1 [11][12]. Lawful compounded access generally requires a prescriber evaluation, a valid prescription, and an eligible ingredient.
What is the FDA 503A status of Wolverine?
Both constituents are in FDA 503A Category 2. The FDA lists BPC-157 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" among bulk substances that may present significant safety risks, effective September 29, 2023 [11]; both are on the July 23-24, 2026 PCAC agenda as candidates under evaluation [13].